{"id":"https://openalex.org/W7214962001","doi":"https://doi.org/10.23750/abm.v95i5.15559","title":"A pilot study of activity of pembrolizumab and low dose chemotherapy in relapsed/refractory T-cell lymphoma: Jordanian experience","display_name":"A pilot study of activity of pembrolizumab and low dose chemotherapy in relapsed/refractory T-cell lymphoma: Jordanian experience","publication_year":2024,"publication_date":"2024-10-29","ids":{"openalex":"https://openalex.org/W7214962001","doi":"https://doi.org/10.23750/abm.v95i5.15559"},"language":"en","primary_location":{"id":"pmh:oai:mattioli1885journals.com:article/15559","doi":"https://doi.org/10.23750/abm.v95i5.15559","is_oa":true,"landing_page_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/15559","pdf_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/download/15559/12104","source":{"id":"https://openalex.org/S4393915150","display_name":"Acta bio-medica dell'Ateneo parmense/Acta biomedica","issn_l":"0392-4203","issn":["0392-4203","2531-6745"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","norway-1","poland-20","russia-white-list-2"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"0392-4203","raw_type":"info:eu-repo/semantics/article"},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/download/15559/12104","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5153598538","display_name":"Salah Abbasi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Abbasi, Salah","raw_affiliation_strings":["Hematology and Oncology, Internal Medicine Department, Al-Khalidi Medical Center, Amman, Jordan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology and Oncology, Internal Medicine Department, Al-Khalidi Medical Center, Amman, Jordan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5120091896","display_name":"Haytham A. M. Dwaik","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114972647","display_name":"University of Jordan","ror":"https://ror.org/05k89ew48","country_code":"JO","type":"education","lineage":["https://openalex.org/I114972647"]}],"countries":["JO"],"is_corresponding":false,"raw_author_name":"Dwaik, Haytham","raw_affiliation_strings":["Internal Medicine department, School of medicine, The University of Jordan, Amman, Jordan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Internal Medicine department, School of medicine, The University of Jordan, Amman, Jordan","institution_ids":["https://openalex.org/I114972647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077139286","display_name":"Layla Abbasi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114972647","display_name":"University of Jordan","ror":"https://ror.org/05k89ew48","country_code":"JO","type":"education","lineage":["https://openalex.org/I114972647"]}],"countries":["JO"],"is_corresponding":false,"raw_author_name":"Abbasi, Layla","raw_affiliation_strings":["Internal Medicine Department, School of Medicine, The University of Jordan, Amman, Jordan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Internal Medicine Department, School of Medicine, The University of Jordan, Amman, Jordan","institution_ids":["https://openalex.org/I114972647"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5153608467","display_name":"Huda Al Hourani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I157392197","display_name":"Hashemite University","ror":"https://ror.org/04a1r5z94","country_code":"JO","type":"education","lineage":["https://openalex.org/I157392197"]}],"countries":["JO"],"is_corresponding":false,"raw_author_name":"Al Hourani, Huda","raw_affiliation_strings":["Department of Clinical Nutrition & Dietetics. The Hashemite University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Nutrition & Dietetics. The Hashemite University","institution_ids":["https://openalex.org/I157392197"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.47894125,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/peripheral-t-cell-lymphoma","display_name":"peripheral T-cell lymphoma","score":0.9909999966621399},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8619999885559082},{"id":"https://openalex.org/keywords/pd-1-pd-l1","display_name":"PD-1/PD-L1","score":0.9070000052452087},{"id":"https://openalex.org/keywords/low-dose-chemotherapy","display_name":"low-dose chemotherapy","score":0.8510000109672546},{"id":"https://openalex.org/keywords/vincristine","display_name":"vincristine","score":0.9390000104904175},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":1.0},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7680000066757202},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7879999876022339},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8920000195503235},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9259999990463257}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.9373999834060669},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9010999798774719},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.695900022983551},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6766999959945679},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.6388000249862671},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5971999764442444},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.41510000824928284},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.3862999975681305},{"id":"https://openalex.org/C169382597","wikidata":"https://www.wikidata.org/wiki/Q21208025","display_name":"Programmed cell death 1","level":5,"score":0.3856000006198883},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.32519999146461487},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.30469998717308044},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.30250000953674316},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.3003999888896942},{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.289000004529953},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.28630000352859497},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.26660001277923584},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2583000063896179},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.25609999895095825},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.25609999895095825}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:mattioli1885journals.com:article/15559","doi":"https://doi.org/10.23750/abm.v95i5.15559","is_oa":true,"landing_page_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/15559","pdf_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/download/15559/12104","source":{"id":"https://openalex.org/S4393915150","display_name":"Acta bio-medica dell'Ateneo parmense/Acta biomedica","issn_l":"0392-4203","issn":["0392-4203","2531-6745"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","norway-1","poland-20","russia-white-list-2"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"0392-4203","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:mattioli1885journals.com:article/15559","doi":"https://doi.org/10.23750/abm.v95i5.15559","is_oa":true,"landing_page_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/15559","pdf_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/download/15559/12104","source":{"id":"https://openalex.org/S4393915150","display_name":"Acta bio-medica dell'Ateneo parmense/Acta biomedica","issn_l":"0392-4203","issn":["0392-4203","2531-6745"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","norway-1","poland-20","russia-white-list-2"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"0392-4203","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/1","score":0.5296711921691895,"display_name":"No poverty"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7214962001.pdf","grobid_xml":"https://content.openalex.org/works/W7214962001.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2928054908","https://openalex.org/W4310108214","https://openalex.org/W2988039113","https://openalex.org/W2984548628","https://openalex.org/W4283380286","https://openalex.org/W4417004315","https://openalex.org/W3096412339","https://openalex.org/W4310118224","https://openalex.org/W3135986745","https://openalex.org/W4390414461"],"abstract_inverted_index":{"Background":[0],"and":[1,12,24,27,86,104,122,138],"aim:":[2],"Peripheral":[3],"T-cell":[4,33],"lymphomas":[5],"(PTCLs)":[6],"are":[7,29,154],"associated":[8],"with":[9,62,70,83,99,147],"poor":[10],"prognosis":[11],"limited":[13],"treatment":[14],"options":[15],"in":[16,32,50,60,144],"the":[17,123,158],"relapsed/refractory":[18],"(R/R)":[19],"setting.":[20],"Programmed":[21],"cell":[22],"death-1":[23],"ligand-1":[25],"(PD-1":[26],"PD-L1)":[28],"frequently":[30],"expressed":[31],"Lymphoma.":[34],"It":[35],"provides":[36],"a":[37],"rationale":[38],"for":[39],"using":[40],"immune":[41],"checkpoint":[42],"inhibitors":[43],"(ICIs)":[44],"to":[45,120,134,156],"manage":[46],"PTCLs.":[47],"Many":[48],"studies":[49,153],"solid":[51],"tumors":[52],"showed":[53],"higher":[54],"efficacy":[55],"of":[56,67,160],"ICIs":[57],"when":[58],"used":[59],"combination":[61],"chemotherapy.":[63],"Methods:":[64],"A":[65],"study":[66],"11":[68],"patients":[69],"R/R":[71,145],"PTCLs":[72],"was":[73,97,114,128],"conducted":[74],"retrospectively.":[75],"They":[76],"were":[77],"treated":[78],"at":[79],"two":[80],"Jordanian":[81],"hospitals":[82],"Pembrolizumab,":[84],"Vincristine,":[85],"Cyclophosphamide":[87],"every":[88],"three":[89,100],"weeks.":[90],"Results:":[91],"The":[92,109],"overall":[93,125],"response":[94,149],"rate":[95],"(ORR)":[96],"63%,":[98],"complete":[101],"responses":[102,107],"(CR)":[103],"four":[105],"partial":[106],"(PR).":[108],"median":[110,124],"progression-free":[111],"survival":[112,126],"(PFS)":[113],"4.0":[115],"months":[116,130],"(95%":[117,131],"CI:":[118,132],"1.7":[119],"11.4),":[121],"(OS)":[127],"17.0":[129],"0.7":[133],"33.2).":[135],"Conclusions:":[136],"Pembrolizumab":[137],"low-dose":[139],"chemotherapy":[140],"demonstrated":[141],"promising":[142],"activity":[143],"PTCL,":[146],"high":[148],"rates.":[150],"Furthermore,":[151],"extensive":[152],"needed":[155],"define":[157],"role":[159],"such":[161],"an":[162],"approach.":[163]},"counts_by_year":[],"updated_date":"2026-10-26T11:51:55.731654","created_date":"2026-10-01T00:00:00"}